Nintedanib Worsens Outcomes Along With Chemo in Advanced Ovarian Cancer

Leggi l'articolo originale


A phase II trial showed that the addition of nintedanib to neoadjuvant chemotherapy did not benefit patients with advanced epithelial ovarian cancer.

Lascia un commento